Mitochondria, Part 4: The Research Frontier
Written By Kevin Wallace.
Real medicine. Early, narrow, and not a product for healthy people.
1. Summary
Mitochondrial medicine is real. As of October 2026 it is early, narrow, and aimed mostly at rare disease. Four lines define the frontier.
| Development | Where it stands | Evidence |
|---|---|---|
| Elamipretide (Forzinity) | FDA accelerated approval, Sept 19, 2025, for knee strength in Barth syndrome, weight at least 30 kg | Approved on an intermediate measure. Controlled trials missed primary endpoints. |
| MOTS-c | No human trial of MOTS-c itself. One 4-week company study of an analog. | Very early |
| Mitochondrial transplantation | Pilot series in children’s hearts. A 5-patient conference report in a bone-marrow disorder. | Early, not randomized |
| Mitochondrial donation in IVF | Eight babies born in the UK, reported July 2025 | First results. Long-term follow-up still required. |
None of these is a tool for healthy people today. For everyday mitochondrial health, Parts 2 and 3 still stand. Exercise, sleep, and metabolic health do more than anything on this frontier.
2. Elamipretide
Elamipretide, also called SS-31, binds cardiolipin, the phospholipid that helps hold the energy chain together on the inner mitochondrial membrane. On September 19, 2025 the FDA granted accelerated approval to Forzinity, from Stealth BioTherapeutics, to improve muscle strength in Barth syndrome in patients weighing at least 30 kg. Barth syndrome is an ultra-rare, life-threatening genetic mitochondrial disease that mainly affects males. This was the first approved treatment for it, and the first FDA-approved mitochondria-targeted drug. (1)
Accelerated approval rests on an intermediate measure, here knee-extensor strength, not on proof of longer walking or longer life. The FDA is requiring a confirmatory randomized trial. The controlled portion of TAZPOWER, a 28-week randomized crossover, missed its primary endpoints. In the open-label extension, 10 patients continued, 8 reached week 168, and the 6-minute walk rose a cumulative 96 meters from the extension baseline. Patients knew they were on the drug. (2)
In MMPOWER-3, 218 people with primary mitochondrial myopathy took 40 mg by daily injection or placebo for 24 weeks. The drug did no better than placebo on walking distance or fatigue. The walking difference was about 3 meters in the wrong direction. A later look at nuclear-gene versus mitochondrial-DNA disease is a hypothesis for another trial, not a finding. (3)
What it means. Real mitochondrial medicine, for one rare disease, on a pathway that still requires confirmation. Nothing here supports elamipretide, or a vial labeled SS-31, for energy, aging, or performance in healthy people.
3. MOTS-c
MOTS-c is a short peptide encoded in mitochondrial DNA. A 2015 paper linked it to metabolic balance in animals. Reviews describe effects on insulin sensitivity and on heart, bone, and inflammation models. They do not cite a human trial of MOTS-c itself. (4)
The nearest human data are a company analog. CohBar’s CB4211, described by the company as an improved MOTS-c analog, was given to 20 obese adults with fatty liver at 25 mg by daily injection for 4 weeks. The company’s 2021 press release reported larger drops in liver enzymes and a 6 percent drop in glucose versus placebo, and no difference in liver fat, which fell in both groups. Injection-site reactions were common. (5) That is a developer’s summary of a 4-week study, not an independent paper.
What it means. An interesting signal in animals, a tiny company study of a related drug, and no human efficacy evidence for MOTS-c itself. Products sold online under that name do not have a trial behind them.
4. Mitochondrial transplantation
The boldest idea is to put healthy mitochondria into damaged tissue. At Boston Children’s Hospital, James McCully and Sitaram Emani took mitochondria from a child’s own skeletal muscle and injected them into heart muscle injured by interrupted blood flow. In a comparison series of children on ECMO after heart surgery, 8 of 10 treated children came off the machine, against 4 of 14 who had revascularization alone, 80 percent versus 29 percent. It was not a randomized trial. (6)
How it works was not the simple story. A 2024 Nature paper from that group found the transplanted mitochondria do not stay and power the cell. They are degraded, and the influx triggers autophagy, the cleanup of poorly performing mitochondria. That is the same repair lever from Parts 1 and 2. (7)
A separate experimental product, MNV-201, enriches a patient’s own blood-forming stem cells with mitochondria. A phase 1 report at the American Society of Hematology meeting in 2025 described no serious treatment-related side effects in the first 5 patients with low-risk myelodysplastic syndrome, and transfusion independence lasting more than 10 months in that early group. A meeting report is not a paper.
What it means. Real human results, from 10 and 5 patients, without a randomized trial. Hospital and trial work. Years from routine use.
5. Mitochondrial donation in IVF
Part 1 noted that mitochondrial DNA is inherited from the mother. A woman who carries a disease-causing mutation can pass on an energy disease of heart, muscle, and brain. Newcastle puts the incidence of inherited mitochondrial DNA disease at about 1 in 5,000 children. The UK legalized mitochondrial donation in 2015. Newcastle received the first clinical license in 2017.
Pronuclear transfer moves the nuclear DNA from the parents’ fertilized egg into a donor egg whose nucleus has been removed. The child has nuclear DNA from both parents and mitochondria from the donor. In July 2025 the Newcastle team reported the pathway in the New England Journal of Medicine. Twenty-two women had commenced or completed pronuclear transfer. Eight babies were born to seven women, including identical twins. All were healthy at birth and meeting developmental milestones. Disease-causing mitochondrial DNA in neonatal blood ranged from undetectable to 16 percent, below the levels at which symptoms are expected. Carryover of a little of the mother’s mitochondria is a known limit. One child developed treatable hyperlipidemia and a heart-rhythm problem. Another had infant myoclonic epilepsy that remitted. The researchers say long-term follow-up is essential. (8)
What it means. A genuine advance, after a decade of regulation. Not a consumer service, and not finished science.
6. Research medicine versus online peptides
The same names show up in two worlds. In medicine, elamipretide is a prescription injection for one rare disease, with an approval that still requires confirmation. Transplantation and donation happen only in hospitals, trials, and licensed programs.
Online, peptides sold under these names are marketed for energy and longevity. In 2023 the FDA placed MOTS-c on a list of bulk substances that raise significant safety concerns for compounding. In April 2026 it left that list after the nomination was withdrawn. Leaving the list is not approval, and it is not permission to compound. In July 2026 an advisory committee voted on compounding several peptides, including MOTS-c. FDA staff had recommended against adding it. The vote was nonbinding. As of this writing it has not created a lawful compounding pathway. (9)
A practical rule. None of these peptides has human evidence of benefit for healthy people. If a product promises mitochondrial renewal from an injection bought online, the research answer is that no one knows what it does, or what is in the vial. The legitimate route runs through a physician and, where it exists, a registered trial.
7. Where we land
The frontier is worth watching, and it is not a shopping list. One drug is approved for one rare disease, on an intermediate endpoint. One peptide has no human trial of its own. Heart mitochondria have been transplanted in a pilot of 10 children. Eight babies have been born after mitochondrial donation, with carryover still on the table. Everyday mitochondrial health is still the work of Parts 2 and 3.
8. Sources
FDA, accelerated approval of Forzinity, September 19, 2025. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome
Thompson et al., Genetics in Medicine, 2024. TAZPOWER open-label extension. https://pubmed.ncbi.nlm.nih.gov/38602181/
Karaa et al., Neurology, 2023. MMPOWER-3. https://www.neurology.org/doi/10.1212/WNL.0000000000207402
Lee et al., Cell Metabolism, 2015, MOTS-c. Zheng, Wei, and Wang, Frontiers in Endocrinology, 2023.
CohBar press release, August 2021, CB4211. Company summary, not an independent paper.
Guariento et al., Journal of Thoracic and Cardiovascular Surgery, 2021. Ten treated children, fourteen comparison patients.
Melero-Martin and colleagues, Nature, 2024, as described by Boston Children’s Hospital. https://answers.childrenshospital.org/mitochondrial-transfer/
Newcastle team, New England Journal of Medicine, July 16, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2503658 Newcastle Hospitals summary, same date.
FDA Category 2 withdrawal, April 2026. Advisory committee, July 23, 2026. Science, July 24, 2026. https://www.science.org/content/article/fda-committee-votes-make-peptides-more-widely-available
